Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026

世界の免疫蛍光アッセイ市場予測:製品別、修理別、疾患別、エンドユーザー別

◆タイトル:Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026
◆商品コード:BT6044
◆調査・発行会社:MarketsandMarkets
◆発行日:2021年2月20日
◆ページ数:204
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は世界の免疫蛍光アッセイ市場規模が2021年26億ドルから2026年35億ドルまで、年平均6.0%成長すると予想しています。本調査レポートでは、免疫蛍光アッセイの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(試薬、器具、抗体、キット、消耗品・付属品)分析、種類別(間接免疫蛍光法、直接免疫蛍光法)分析、疾患別(癌、感染症、心血管疾患、自己免疫疾患、その他)分析、エンドユーザー別(製薬・バイオテクノロジー企業、学術研究機関、病院・診断センター、委託研究機関)分析、地域別分析、競争状況、企業情報などをまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の免疫蛍光アッセイ市場規模:製品別(試薬、器具、抗体、キット、消耗品・付属品)
・世界の免疫蛍光アッセイ市場規模:種類別(間接免疫蛍光法、直接免疫蛍光法)
・世界の免疫蛍光アッセイ市場規模:疾患別(癌、感染症、心血管疾患、自己免疫疾患、その他)
・世界の免疫蛍光アッセイ市場規模:エンドユーザー別(製薬・バイオテクノロジー企業、学術研究機関、病院・診断センター、委託研究機関)
・世界の免疫蛍光アッセイ市場規模:地域別
・競争状況
・企業情報

“The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period.”
The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.

“The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period”
The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment’s high growth rate.

“Indirect immunofluorescence segment accounted for the highest CAGR”
Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.

“Cancer segment accounted for the highest CAGR”
Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment’s growth.

“Hospitals & Diagnostic Centers segment accounted for the highest CAGR”
Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment’s growth.

“Asia Pacific: The fastest-growing country in the Immunofluorescence assay market”
The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America- 50%, Europe- 32%, APAC-10%, RoW- 8%

Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Abcam plc (UK)
• Bio-Rad Laboratories, Inc. (US)
• PerkinElmer Inc. (US)
• Merck KGaA (Germany)
• Werfen Company (Spain)
• Cell Signaling Technology, Inc. (US)
• MEDIPAN GmbH (Germany)
• Sino Biological, Inc. (China)
• Danaher Corporation (US)
• Maravai LifeSciences (US)
• Enzo Biochem, Inc. (US)
• Becton, Dickinson and Company (US)
• Olympus Corporation (Japan)
• Nikon Corporation (Japan)
• Bruker Corporation (US)
• Agilent Technologies (US)
• Zyagen, Inc. (US)
• Cellabs (Australia)
• J. Mitra & Co. Pvt. Ltd. (India)
• Abnova Corporation (Taiwan)
• EpiGentek Group (US)
• Elabscience, Inc. (US)
• AESKU GROUP GmbH (Germany)
• MaxVision Biosciences Inc. (Canada)

Research Coverage:
This report provides a detailed picture of the Immunofluorescence assay market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.2.1 INCLUSIONS & EXCLUSIONS 21
1.3 MARKET SCOPE 22
1.3.1 MARKETS COVERED 22
FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.3.3 CURRENCY 23
1.4 STAKEHOLDERS 23
1.5 LIMITATIONS 23
1.6 SUMMARY OF CHANGES 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN 25
2.1.1 SECONDARY DATA 26
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 27
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 27
2.1.2.1 Key data from primary sources 28
2.2 MARKET SIZE ESTIMATION 28
2.2.1 BOTTOM-UP APPROACH 29
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 29
2.2.2 TOP-DOWN APPROACH 30
FIGURE 5 TOP-DOWN APPROACH 30
2.2.3 GROWTH FORECAST 30
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 31
FIGURE 6 DATA TRIANGULATION METHODOLOGY 31
2.4 ASSUMPTIONS FOR THE STUDY 32
3 EXECUTIVE SUMMARY 33
FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 33
FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2018 VS. 2023 (USD MILLION) 34
FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 34
FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 35
FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS MARKET 36
4 PREMIUM INSIGHTS 37
4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW 37
FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 37
4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE & COUNTRY (2020) 38
FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020 38
4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 39
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 KEY MARKET DYNAMICS 40
FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
5.2.1 DRIVERS 41
5.2.1.1 Increasing prevalence of chronic diseases 41
TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040 41
5.2.1.2 Rising R&D and healthcare spending 42
FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010–2016 42
FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015–2018 43
5.2.1.3 Growing industry-academia collaboration 43
5.2.1.4 Increasing government funding for life science research 44
TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020) 44
5.2.1.5 Growing awareness about early disease detection 44
5.2.2 RESTRAINTS 45
5.2.2.1 High instrument costs 45
5.2.3 OPPORTUNITIES 45
5.2.3.1 High growth opportunities in emerging markets 45
TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES,
2019 VS. 2030 VS. 2045 45
5.2.4 CHALLENGES 46
5.2.4.1 Quality concerns over research antibodies 46
5.2.4.2 Lack of skilled professionals 46
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 46
5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET 47
TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS 47
5.4 PRICING ANALYSIS 48
TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES
(IN USD) 48
5.5 VALUE CHAIN ANALYSIS 49
FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 49
5.6 SUPPLY CHAIN ANALYSIS 50
FIGURE 19 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES 50
5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET 51
FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET 51
5.8 PESTLE ANALYSIS 52
6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT 53
6.1 INTRODUCTION 54
TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 54
6.2 REAGENTS 54
TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 55
TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 55
6.2.1 STAINS & DYES 56
6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020 56
TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 56
6.2.2 MEDIA & SERA 57
6.2.2.1 Serum-free media eliminates the risk of contamination by viruses 57
TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 57
6.2.3 FIXATIVES 58
6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules 58
TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 58
6.2.4 BUFFERS 59
6.2.4.1 Buffers are widely used in drug development applications 59
TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY,
2019-2026(USD MILLION) 59
6.2.5 PROBES 60
6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities 60
TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 60
6.2.6 SOLVENTS 61
6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays 61

TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 61
6.2.7 OTHER REAGENTS 62
TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 62
6.3 INSTRUMENTS 63
TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 63
TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 63
6.3.1 MICROSCOPES 64
6.3.1.1 Technological advancements in microscopy techniques propel segment growth 64
TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 64
6.3.2 IMAGING ANALYSIS SYSTEMS 65
6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research 65
TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2019-2026 (USD MILLION) 65
6.4 ANTIBODIES 66
TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026(USD MILLION) 66
TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 67
6.4.1 PRIMARY ANTIBODIES 68
6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth 68
TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 68
6.4.2 SECONDARY ANTIBODIES 69
6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies 69
TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 69
6.5 KITS 70
6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT 70
TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY,
2019-2026(USD MILLION) 70
6.6 CONSUMABLES & ACCESSORIES 71
TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET,
BY COUNTRY, 2019-2026 (USD MILLION) 71

7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE 72
7.1 INTRODUCTION 73
TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 73
TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES 73
7.2 INDIRECT IMMUNOFLUORESCENCE 74
7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020 74
TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET,
BY REGION/COUNTRY, 2019–2026 (USD MILLION) 74
7.3 DIRECT IMMUNOFLUORESCENCE 75
7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET 75
TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE 76
8.1 INTRODUCTION 77
TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 77
8.2 CANCER 77
8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020 77
TABLE 32 CANCER PREVALENCE, BY TYPE (2018) 77
TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025 78
TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION) 78
8.3 INFECTIOUS DISEASES 79
8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES 79
TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 79
8.4 CARDIOVASCULAR DISEASES 80
8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES 80
TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 80
8.5 AUTOIMMUNE DISEASES 81
8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT 81
TABLE 37 PREVALENCE OF AIDS 81
TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 82

8.6 OTHER DISEASES 82
TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 83
9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER 84
9.1 INTRODUCTION 85
TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026(USD MILLION) 85
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 85
9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020 85
TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION,
2019-2026 (USD MILLION) 86
9.3 ACADEMIC & RESEARCH INSTITUTES 86
9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH 86
TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION) 87
9.4 HOSPITALS & DIAGNOSTIC CENTERS 87
9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT 87
TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION) 88
9.5 CONTRACT RESEARCH ORGANIZATIONS 89
9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS 89
TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION) 89
10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION 90
10.1 INTRODUCTION 91
TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION,
2019–2026 (USD MILLION) 91
10.2 NORTH AMERICA 92
FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT 92
TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 93
TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 93
TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 94
TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 94
TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION) 94
TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION) 94
TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION) 95
10.2.1 US 95
10.2.1.1 The US dominates the North American market in terms of market share 95
TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES,
FY 2019 VS. FY 2020 (USD BILLION) 96
TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 96
TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 96
TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 97
TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 97
TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 97
TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 97
TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 98
10.2.2 CANADA 98
10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada 98
TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 99
TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 99
TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 99
TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 100
TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 100
TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 100
TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 101
10.3 EUROPE 101
TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 102
TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 102
TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 102
TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 103
TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 103
TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 103
TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 103
TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 104
10.3.1 GERMANY 104
10.3.1.1 Germany holds the largest share of the European market 104
TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015–2019 104
TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 105
TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 106
TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 106
TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 106
TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 107
10.3.2 UK 107
10.3.2.1 Growing R&D investments drive the market in the UK 107
TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 108
TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 108
TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 108
TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 109
TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 109
TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 109
TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 109
10.3.3 FRANCE 110
10.3.3.1 Rising research activity supports market growth in France 110
TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 110
TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 112
TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 112
10.3.4 ITALY 113
10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market 113
TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 113
TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 114
TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 114
TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 114
TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 115
TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 115
10.3.5 SPAIN 116
10.3.5.1 Rising prevalence of chronic disease to support the market growth 116
TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 116
TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 118
TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 118
TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 118
10.3.6 REST OF EUROPE 119
TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 119
TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION) 121
TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION) 121
TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION) 121
10.4 ASIA PACIFIC 122
FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET SNAPSHOT 123
TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY,
2019-2026 (USD MILLION) 124
TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 124
TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 124
TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 125
TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 125
TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 125
TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 125
TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 126
10.4.1 JAPAN 126
10.4.1.1 Japan is the largest market for immunofluorescence assays
in the APAC 126
TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 127
TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 127
TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 127
TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 128
TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 128
TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 128
TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 129
10.4.2 CHINA 129
10.4.2.1 China is the fastest-growing market for immunofluorescence assays 129
TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 130
TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 130
TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 130
TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 131
TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 131
TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 131
TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 132
10.4.3 INDIA 132
10.4.3.1 Increasing government spending on healthcare to support market growth 132
TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 133
TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 133
TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 133
TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 134
TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 134
TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 134
TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 134
10.4.4 REST OF ASIA PACIFIC 135
TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 135
TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 136
TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 136
TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 136
TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 137
TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 137
TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 137
10.5 LATIN AMERICA 138
10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH 138
TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION) 138
TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION) 139
TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION) 139
TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION) 139
TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 140
TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION) 140
TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION) 140
10.6 MIDDLE EAST & AFRICA 141
10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION 141
TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION) 141
TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 142
TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION) 142
TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION) 142
TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION) 143
TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION) 143
TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION) 143
11 COMPETITIVE LANDSCAPE 144
11.1 OVERVIEW 144
FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020) 144
11.2 MARKET SHARE ANALYSIS 145
FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019) 145
FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE,
BY KEY PLAYER (2019) 146
11.3 COMPETITIVE SCENARIO 147
11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020 147
11.3.2 PRODUCT LAUNCHES & APPROVALS 147
TABLE 170 PRODUCT LAUNCHES & APPROVALS 147
11.3.3 AGREEMENTS & COLLABORATIONS 148
TABLE 171 AGREEMENTS & COLLABORATIONS 148
11.3.4 ACQUISITIONS 148
TABLE 172 ACQUISITIONS 148
11.3.5 EXPANSIONS 149
TABLE 173 EXPANSIONS 149
11.3.6 OTHER DEVELOPMENTS 149
TABLE 174 OTHER DEVELOPMENTS 149
11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY 150
11.4.1 VENDOR EXCLUSION CRITERIA 150
11.4.2 STARS 150
11.4.3 EMERGING LEADERS 150
11.4.4 PERVASIVE PLAYERS 150
11.4.5 PARTICIPANTS 150
FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING 151
11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES 151
11.5.1 PROGRESSIVE COMPANIES 151
11.5.2 STARTING BLOCKS 152
11.5.3 RESPONSIVE COMPANIES 152
11.5.4 DYNAMIC COMPANIES 152
FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES 152
12 COMPANY PROFILES 153
(Business overview, Products offered, Recent developments & MnM View)*
12.1 THERMO FISHER SCIENTIFIC, INC. 153
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019) 153
12.2 ABCAM PLC 157
FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020) 157
12.3 BIO-RAD LABORATORIES, INC. 160
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019) 160
12.4 PERKINELMER, INC. 163
FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019) 163
12.5 MERCK KGAA 166
FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019) 166
12.6 WERFEN COMPANY 169
FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019) 169
12.7 CELL SIGNALING TECHNOLOGY, INC. 171
12.8 MEDIPAN GMBH 173
12.9 SINO BIOLOGICAL, INC. 174
12.10 DANAHER CORPORATION 175
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 175

12.11 MARAVAI LIFESCIENCES 178
FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019) 178
12.12 ENZO BIOCHEM, INC. 181
FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019) 181
12.13 BECTON, DICKINSON AND COMPANY (BD) 183
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 183
12.14 OLYMPUS CORPORATION 185
FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020) 185
12.15 NIKON CORPORATION 187
FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020) 187
12.16 BRUKER CORPORATION 189
12.17 AGILENT TECHNOLOGIES 190
12.18 ZYAGEN, INC. 191
12.19 CELLABS 192
12.20 J. MITRA & CO. PVT. LTD. 193
12.21 ABNOVA CORPORATION 193
12.22 EPIGENTEK GROUP 194
12.23 ELABSCIENCE, INC. 194
12.24 AESKU.GROUP GMBH 194
12.25 MAXVISION BIOSCIENCES, INC. 194
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13 APPENDIX 195
13.1 INDUSTRY INSIGHTS 195
13.2 DISCUSSION GUIDE 195
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 200
13.4 AVAILABLE CUSTOMIZATIONS 202
13.5 RELATED REPORTS 202
13.6 AUTHOR DETAILS 203



★調査レポート[世界の免疫蛍光アッセイ市場予測:製品別、修理別、疾患別、エンドユーザー別] ( Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026 / BT6044) 販売に関する免責事項
[世界の免疫蛍光アッセイ市場予測:製品別、修理別、疾患別、エンドユーザー別] ( Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026 / BT6044) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆